Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Biogen Inc (BIIB)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 69,903,704
  • Shares Outstanding, K 201,440
  • Annual Sales, $ 12,274 M
  • Annual Income, $ 2,539 M
  • 36-Month Beta 0.90
  • Price/Sales 5.67
  • Price/Cash Flow 12.76
  • Price/Book 5.68

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 24 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/18
See More
  • Average Estimate 6.80
  • Number of Estimates 25
  • High Estimate 7.23
  • Low Estimate 6.49
  • Prior Year 6.31
  • Growth Rate Est. (year over year) +7.77%

Price Performance

See More
Period Period Low Period High Performance
1-Month
332.48 +4.37%
on 09/18/18
355.94 -2.51%
on 08/30/18
+4.69 (+1.37%)
since 08/24/18
3-Month
285.32 +21.62%
on 06/28/18
388.67 -10.72%
on 07/25/18
+50.98 (+17.22%)
since 06/22/18
52-Week
249.17 +39.27%
on 04/24/18
388.67 -10.72%
on 07/25/18
+28.56 (+8.97%)
since 09/22/17

Most Recent Stories

More News
S&P 500 Q2 2018 Buybacks Increase 58.7% Year-Over-Year to Record $190.6 Billion

S&P Dow Jones Indices ("S&P DJI") today announced preliminary results indicating that S&P 500® stock buybacks, or share repurchases, totaled $190.6 billion for Q2 2018, displacing the prior quarterly...

GOOG : 1,173.37 (+0.62%)
AAPL : 220.79 (+1.44%)
CELG : 87.56 (-0.18%)
AVGO : 249.45 (+0.54%)
CSCO : 48.44 (-0.25%)
C : 73.84 (-0.42%)
BAC : 30.74 (-0.93%)
JPM : 116.72 (-0.96%)
ORCL : 51.24 (+0.27%)
ABBV : 93.42 (+1.26%)
AMGN : 207.21 (+1.03%)
MSFT : 114.67 (+0.36%)
WFC : 54.26 (-1.33%)
INTC : 46.91 (+0.54%)
UNP : 163.18 (-1.10%)
V : 149.11 (-0.63%)
SPGI : 210.30 (-0.55%)
FB : 165.41 (+1.52%)
HD : 207.99 (-2.07%)
BIIB : 347.02 (+0.47%)
BA : 367.99 (-1.14%)
3 Drug/Biotech Stocks in Focus on World Alzheimer's Day

We take a look at companies with prospective Alzheimer's Disease candidates in pipeline on World Alzheimer's Day.

PTIE : 0.96 (+0.74%)
AGN : 187.98 (-1.74%)
RHHBY : 30.1700 (-1.47%)
BIIB : 347.02 (+0.47%)
The Zacks Analyst Blog Highlights: Wells Fargo, Schlumberger, Biogen, American Express and Illinois Tool Works

The Zacks Analyst Blog Highlights: Wells Fargo, Schlumberger, Biogen, American Express and Illinois Tool Works

WFC : 54.26 (-1.33%)
SLB : 61.60 (+0.77%)
AXP : 109.85 (-0.95%)
ITW : 146.02 (-1.63%)
BIIB : 347.02 (+0.47%)
Top Research Reports for Wells Fargo, Schlumberger & Biogen

Top Research Reports for Wells Fargo, Schlumberger & Biogen

WFC : 54.26 (-1.33%)
SLB : 61.60 (+0.77%)
AXP : 109.85 (-0.95%)
ITW : 146.02 (-1.63%)
GSK : 40.20 (-0.25%)
BIIB : 347.02 (+0.47%)
Acorda (ACOR) Stock Dips, FDA Delays Decision on Inbrija

The FDA defers decision by three months regarding the NDA of Acorda's (ACOR) Parkinson's disease candidate Inbrija for the treatment of OFF periods.

MYL : 38.19 (-2.05%)
ACOR : 18.75 (+3.02%)
TEVA : 23.86 (-2.05%)
BIIB : 347.02 (+0.47%)
Alkermes Expands Study to Evaluate ALKS 4230-Keytruda Combo

Alkermes expands a phase I study to evaluate its immuno-oncology candidate, ALKS 4230, in combination with Keytruda in patients with advanced solid tumors.

LGND : 268.34 (+3.27%)
MRK : 70.78 (-0.45%)
ALKS : 42.17 (+1.47%)
BIIB : 347.02 (+0.47%)
Acorda Gets Unfavorable Court Ruling for Ampyra, Stock Down

Acorda Therapeutics' (ACOR) stock slumps after a Federal Circuit Court rules against its appeal to protect patents pertaining to its key multiple sclerosis drug, Ampyra

MYL : 38.19 (-2.05%)
ACOR : 18.75 (+3.02%)
TEVA : 23.86 (-2.05%)
BIIB : 347.02 (+0.47%)
Biogen Begins Phase III Study on Ischemic Stroke Candidate

Biogen (BIIB) enrolls first patient in a phase III study evaluating BIIB093 for prevention and treatment of severe cerebral edema in large hemispheric infarction.

ENDP : 16.29 (+1.05%)
PCRX : 50.45 (-0.10%)
BIIB : 347.02 (+0.47%)
BSTC : 58.38 (-0.24%)
Biogen Enrolls First Patient in Global Phase 3 Study of BIIB093 (IV Glibenclamide) for Large Hemispheric Infarction

- CHARM study will evaluate IV glibenclamide for the prevention and treatment of severe cerebral edema in LHI, one of the most severe types of ischemic stroke with limited treatment options

BIIB : 347.02 (+0.47%)
Biogen Inc Set to Possibly Pullback After Yesterday's Rally of 1.75%

Biogen Inc (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $346.16 to a high of $352.02. Yesterday, the shares gained 1.8%, which took the trading range above the 3-day high of $348.00...

BIIB : 347.02 (+0.47%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Strengthening short term outlook on maintaining the current direction.

Longer term, the trend strength is Weak. Long term indicators fully support a continuation of the trend.

See More Share

Trade BIIB with:

Business Summary

Biogen is a leading biopharmaceutical company engaged in the research, development and marketing of targeted therapies for the treatment of cancer, autoimmune and inflammatory diseases. The company owns industry leading brands for the treatment of multiple sclerosis, next-generation treatments for hemophilia,...

See More

Key Turning Points

2nd Resistance Point 351.45
1st Resistance Point 349.23
Last Price 347.02
1st Support Level 343.33
2nd Support Level 339.65

See More

52-Week High 388.67
Last Price 347.02
Fibonacci 61.8% 335.38
Fibonacci 50% 318.92
Fibonacci 38.2% 302.46
52-Week Low 249.17

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar